[go: up one dir, main page]

CY1107711T1 - Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων - Google Patents

Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων

Info

Publication number
CY1107711T1
CY1107711T1 CY20071101054T CY071101054T CY1107711T1 CY 1107711 T1 CY1107711 T1 CY 1107711T1 CY 20071101054 T CY20071101054 T CY 20071101054T CY 071101054 T CY071101054 T CY 071101054T CY 1107711 T1 CY1107711 T1 CY 1107711T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
particles
treatment against
composition
against acid
Prior art date
Application number
CY20071101054T
Other languages
Greek (el)
English (en)
Inventor
Anders Pettersson
Christer Nyström
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20412702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107711(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of CY1107711T1 publication Critical patent/CY1107711T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
CY20071101054T 1998-09-24 2007-08-07 Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων CY1107711T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803240A SE9803240D0 (sv) 1998-09-24 1998-09-24 A pharmaceutical composition having a rapid action
EP99952867A EP1115383B1 (fr) 1998-09-24 1999-09-24 Traitment des maladies aigues par l'administration par voie sub-linguale d'une composition pharmaceutique

Publications (1)

Publication Number Publication Date
CY1107711T1 true CY1107711T1 (el) 2013-04-18

Family

ID=20412702

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20071101054T CY1107711T1 (el) 1998-09-24 2007-08-07 Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων
CY20131100974T CY1114620T1 (el) 1998-09-24 2013-11-04 Φαρμακευτικη συνθεση προς υπογλωσσια χορηγηση
CY20141100588T CY1115685T1 (el) 1998-09-24 2014-08-04 Φαρμακευτικη συνθεση προς αγωγη εναντι αϋπνιας μεσω υπογλωσσιας χορηγησης
CY20141100730T CY1115688T1 (el) 1998-09-24 2014-09-10 Φαρμακευτικη συνθεση που περιλαμβανει φεντανυλη προς αγωγη εναντι οξεος ή παροξυσμικου πονου μεσω υπογλωσσιας χορηγησης
CY20171101261T CY1119644T1 (el) 1998-09-24 2017-11-30 Φαρμακευτικη συνθεση ταχειας δρασης που περιλαμβανει βουπρενορφινη

Family Applications After (4)

Application Number Title Priority Date Filing Date
CY20131100974T CY1114620T1 (el) 1998-09-24 2013-11-04 Φαρμακευτικη συνθεση προς υπογλωσσια χορηγηση
CY20141100588T CY1115685T1 (el) 1998-09-24 2014-08-04 Φαρμακευτικη συνθεση προς αγωγη εναντι αϋπνιας μεσω υπογλωσσιας χορηγησης
CY20141100730T CY1115688T1 (el) 1998-09-24 2014-09-10 Φαρμακευτικη συνθεση που περιλαμβανει φεντανυλη προς αγωγη εναντι οξεος ή παροξυσμικου πονου μεσω υπογλωσσιας χορηγησης
CY20171101261T CY1119644T1 (el) 1998-09-24 2017-11-30 Φαρμακευτικη συνθεση ταχειας δρασης που περιλαμβανει βουπρενορφινη

Country Status (29)

Country Link
US (8) US6761910B1 (fr)
EP (5) EP2236133B1 (fr)
JP (1) JP3381220B2 (fr)
KR (1) KR100760536B1 (fr)
CN (1) CN1173694C (fr)
AT (1) ATE365540T1 (fr)
AU (1) AU764346B2 (fr)
BG (1) BG65502B1 (fr)
BR (1) BRPI9913945B8 (fr)
CA (3) CA2820588C (fr)
CY (5) CY1107711T1 (fr)
CZ (2) CZ2008315A3 (fr)
DE (1) DE69936393T2 (fr)
DK (5) DK2236132T3 (fr)
EE (3) EE04927B1 (fr)
ES (5) ES2498095T3 (fr)
HU (2) HU230468B1 (fr)
IL (1) IL142135A0 (fr)
LU (1) LU92636I2 (fr)
MX (1) MXPA01003068A (fr)
NO (1) NO332226B1 (fr)
NZ (1) NZ510284A (fr)
PL (2) PL204264B1 (fr)
PT (5) PT1652518E (fr)
RU (1) RU2193879C1 (fr)
SE (1) SE9803240D0 (fr)
SK (1) SK283302B6 (fr)
TR (1) TR200100855T2 (fr)
WO (1) WO2000016750A1 (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
PT1307194E (pt) 2000-07-31 2008-05-27 Nycomed Danmark Aps Composição à base de fentanil para administração nasal
ES2380654T3 (es) * 2000-12-07 2012-05-17 Nycomed Gmbh Tableta de desintegración rápida que comprende un ingrediente activo lábil en medio ácido
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
CA2472103A1 (fr) * 2002-01-25 2003-08-07 Santarus, Inc. Administration par voie muqueuse d'inhibiteurs de la pompe a protons
IL164152A0 (en) * 2002-03-26 2005-12-18 Teva Pharma Drug microparticles
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
AU2004208644B2 (en) * 2003-01-31 2009-07-23 Orexo Ab A rapid-acting pharmaceutical composition
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
ITRM20030288A1 (it) * 2003-06-10 2004-12-11 Valerio Cioli Somministrazione sublinguale di antinfiammatori non steroidei (fans)
WO2005039640A1 (fr) * 2003-10-03 2005-05-06 Allergan Inc. Compositions contenant des peptides en trefle et/ou des mucoadhesifs et des promedicaments d'un inhibiteur de pompe a proton
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050142197A1 (en) * 2003-12-31 2005-06-30 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2005065317A2 (fr) * 2003-12-31 2005-07-21 Cima Labs Inc. Forme posologique orale effervescente a base de fentanyl et procedes permettant d'administrer du fentanyl
ATE500821T1 (de) 2003-12-31 2011-03-15 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US7658945B2 (en) * 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US8163114B2 (en) * 2004-04-07 2012-04-24 New Jersey Institute Of Technology Netshape manufacturing processes and compositions
ES2660172T3 (es) * 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
GB0423800D0 (en) 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
EP1836101A4 (fr) * 2005-01-14 2008-03-19 Cima Labs Inc Plaquette non dechirable de protection a l'epreuve des enfants
ES2375974T3 (es) * 2005-01-14 2012-03-07 Cima Labs Inc. Envase de pastillas del tipo de doblar y despegar.
WO2006085101A2 (fr) * 2005-02-10 2006-08-17 Orexo Ab Nouvelles compositions pharmaceutiques utiles pour l'administration transmuqueuse de medicaments
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
CN101151021A (zh) * 2005-03-28 2008-03-26 奥瑞克索股份公司 用于疼痛治疗的新药物组合物
NZ560826A (en) * 2005-03-28 2009-06-26 Orexo Ab Composition comprising weak acid and particulate L-dopa useful in the treatment of parkinson's disease
JP2008534562A (ja) * 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット 偏頭痛の治療に有用な新しい製薬組成物
ZA200710205B (en) * 2005-05-25 2009-03-25 Transcept Pharmaceuticals Inc Solid compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20060276501A1 (en) * 2005-05-25 2006-12-07 Transoral Pharmaceuticals, Inc. Solid compositions for treating middle-of-the-night insomnia
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8486972B2 (en) * 2006-01-25 2013-07-16 Insys Therapeutics, Inc. Sublingual fentanyl spray
BRPI0709872A2 (pt) * 2006-04-03 2011-07-26 Teva Pharma micropartÍculas de drogas
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
EP2037895A4 (fr) * 2006-05-23 2009-12-02 Orahealth Corp Trochisques à base de xilitol et leurs procédés d'utilisation
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
WO2008070795A2 (fr) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Polythérapie utilisant de la doxépine à faible dose pour l'amélioration du sommeil
MX2009006672A (es) 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
DE102007010109A1 (de) * 2007-02-28 2008-09-04 Henkel Ag & Co. Kgaa Wirkstoffträgersysteme
WO2008108286A1 (fr) * 2007-03-02 2008-09-12 Teika Pharmaceutical Co., Ltd. Composition médicinale pour une absorption transdermique, unité de stockage de la composition médicinale et préparation par absorption transdermique utilisant celle-ci
US9339463B2 (en) * 2007-12-06 2016-05-17 Michael Zamloot Micronized opioid compositions having a specific particle size distribution
WO2009075782A1 (fr) 2007-12-06 2009-06-18 Durect Corporation Procédés utiles dans le traitement de la douleur, d'états rhumatismaux ou d'inflammations associées à un état chronique
WO2009098169A1 (fr) * 2008-02-05 2009-08-13 Alpex Pharma Sa Comprimés à dissolution orale ayant un aspect moucheté
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
EP2111857A1 (fr) * 2008-04-25 2009-10-28 Acino AG Système thérapeutique transdermique destiné à l'application de fentanyle ou d'une matière analogue
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
SE533540C2 (sv) * 2008-12-19 2010-10-19 Neoinvent Medical Engineering Ab Administrerinssystem för administrering av en substans i munhålan
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
JP5702526B2 (ja) 2009-04-30 2015-04-15 Ｅｓファイバービジョンズ株式会社 抗ウイルス性を有する硫酸化セルロースを担持させた繊維集合体
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
CN102933207B (zh) 2009-10-30 2018-02-02 Ix生物医药有限公司 快速溶解固体剂型
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
EP2519229A2 (fr) 2009-12-29 2012-11-07 Novartis AG Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
EP2801625B1 (fr) 2010-07-02 2017-11-01 University Of Virginia Patent Foundation Approche génétique moléculaire pour le traitement et le diagnostic de dépendance à l'alcool et aux drogues
ITMI20101426A1 (it) * 2010-07-29 2012-01-30 Altergon Sa Composizione contenente condroitin solfato
FR2967066B1 (fr) * 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
US8722636B2 (en) * 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
WO2012112940A1 (fr) 2011-02-18 2012-08-23 Kythera Biopharmaceuticals, Inc. Traitement de graisse sous-mentale
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
CA2835203A1 (fr) 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions et procedes pour le traitement du cancer
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
EP2915525B1 (fr) 2011-09-19 2021-08-11 Orexo AB Comprimés résistant aux abus à administration sublinguale contenant de la buprénorphine et de la naloxone
SG11201407081PA (en) 2012-05-02 2014-11-27 Orexo Ab New alfentanil composition for the treatment of acute pain
EP3446685A1 (fr) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Libération auto-régulée d'ingrédient pharmaceutique actif
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
KR20160108828A (ko) 2013-11-11 2016-09-20 임팩스 라보라토리즈, 인코포레이티드 신속하게 붕괴되는 제형 및 사용 방법
WO2016007245A1 (fr) 2014-07-08 2016-01-14 Insys Pharma, Inc. Aerosol sublingual de naloxone
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11058856B2 (en) 2014-12-23 2021-07-13 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2017040607A1 (fr) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Procédés et compositions pour la libération auto-régulée d'un ingrédient pharmaceutique actif
US20170119660A1 (en) * 2015-10-29 2017-05-04 Solubest Ltd Pharmaceutical compositions for transmucosal delivery
WO2017177037A1 (fr) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions et méthodes pour le traitement du cancer
MY205229A (en) 2016-07-06 2024-10-08 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
CN107157994A (zh) * 2017-06-09 2017-09-15 董鹏 一种托拉塞米的舌下口服制剂

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
US4229447A (en) * 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4432975A (en) * 1981-04-13 1984-02-21 Icn Pharmaceuticals, Inc. Process for introducing vitamin B-12 into the bloodstream
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
DE3715682A1 (de) * 1987-05-11 1988-11-24 Stefan Dr Lueth Vorrichtung zum herstellen eines zweikomponentengemisches
SE8800080L (sv) 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
SE8803935L (sv) * 1988-10-31 1990-05-01 Kabivitrum Ab Laekemedelskomposition
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
PT96059B (pt) * 1989-12-04 1998-07-31 Searle & Co Sistema de camada unica para a administracao de um medicamento por via transdermica
SE8904298D0 (sv) * 1989-12-21 1989-12-21 Astra Ab New compounds
US5370862A (en) * 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
RU2007729C1 (ru) * 1991-05-05 1994-02-15 Донецкий государственный медицинский институт им.М.Горького Способ дифференциальной диагностики острой почечной недостаточности и функциональной олигурии
US5173486A (en) * 1991-08-26 1992-12-22 Bristol-Myers Squibb Company Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
FR2694194B1 (fr) 1992-07-31 1994-11-04 Health Business Dev Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel.
JPH0665103A (ja) 1992-08-13 1994-03-08 ▲寛▼治 ▲高▼田 向精神薬のための速吸収性舌下投与製剤
WO1994006426A1 (fr) 1992-09-21 1994-03-31 Qin Bo Yi Procedes d'identification et d'utilisation d'analgesiques opioides de faible dependance ou de non dependance
WO1995001782A2 (fr) 1993-07-09 1995-01-19 R.P. Scherer Corporation Procede de fabrication de formes galeniques de medicaments lyophilises
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
DE19652188C2 (de) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
DE19652268C2 (de) 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19749724A1 (de) * 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
KR100289471B1 (ko) * 1998-01-19 2001-09-17 김충섭 휀타닐계마취제의이식형서방성제제
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6264974B1 (en) * 1998-07-07 2001-07-24 Salvagnini Italia Spa Buccal and sublingual administration of physostigmine
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
EP1005863A1 (fr) 1998-12-04 2000-06-07 Synthelabo Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
WO2001030391A2 (fr) 1999-10-27 2001-05-03 Farmarc Nederland Bv Composition pharmaceutique contenant du midazolam
WO2001078725A2 (fr) * 2000-04-13 2001-10-25 Synthon B.V. Formulations a liberation modifiee contenant un agent hypnotique
CN1290525A (zh) 2000-10-10 2001-04-11 北京万全阳光医药科技有限公司 冷冻干燥的扎来普隆速溶口服组合物
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
BR0306843A (pt) 2002-01-10 2004-12-07 Biovail Lab Inc Formulações sedativas de não-benzodiazepina
CN1418631A (zh) 2002-12-19 2003-05-21 王登之 治疗失眠的佐匹克隆口腔崩解片及其制备方法
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets

Also Published As

Publication number Publication date
NO20011473D0 (no) 2001-03-22
JP3381220B2 (ja) 2003-02-24
EP1115383B1 (fr) 2007-06-27
EE200700030A (et) 2007-08-15
NO20011473L (no) 2001-05-23
EP2805716B1 (fr) 2017-09-13
SK4022001A3 (en) 2001-11-06
US20070031502A1 (en) 2007-02-08
HUP0103856A3 (en) 2003-11-28
DK2236132T3 (da) 2014-08-04
CA2820588A1 (fr) 2000-03-30
CA2629988C (fr) 2014-01-07
US7910132B2 (en) 2011-03-22
EP2805716A1 (fr) 2014-11-26
NZ510284A (en) 2003-05-30
US6761910B1 (en) 2004-07-13
HU230468B1 (hu) 2016-07-28
EE200800028A (et) 2008-08-15
DK1652518T3 (da) 2013-10-28
DK1115383T3 (da) 2007-07-30
PT2236132E (pt) 2014-07-31
ATE365540T1 (de) 2007-07-15
LU92636I2 (fr) 2015-03-20
EP1115383A1 (fr) 2001-07-18
US20130195976A1 (en) 2013-08-01
PT2805716T (pt) 2017-12-21
BG105379A (en) 2001-12-29
US20140030336A1 (en) 2014-01-30
ES2498095T3 (es) 2014-09-24
CZ20011029A3 (cs) 2001-08-15
HK1091722A1 (en) 2007-01-26
US8454996B2 (en) 2013-06-04
CY1114620T1 (el) 2016-10-05
EE04927B1 (et) 2007-12-17
CZ306387B6 (cs) 2016-12-28
PT2236133E (pt) 2014-07-16
CZ302975B6 (cs) 2012-02-01
NO332226B1 (no) 2012-07-30
US20120315330A1 (en) 2012-12-13
ES2644770T3 (es) 2017-11-30
CA2820588C (fr) 2015-11-17
KR20010075315A (ko) 2001-08-09
KR100760536B1 (ko) 2007-10-04
CZ2008315A3 (cs) 2016-12-28
HUP0103856A2 (hu) 2002-02-28
PT1115383E (pt) 2007-07-13
ES2289829T3 (es) 2008-02-01
AU6492799A (en) 2000-04-10
US20080286368A1 (en) 2008-11-20
EP2236133A1 (fr) 2010-10-06
HK1148457A1 (en) 2011-09-09
HK1203144A1 (en) 2015-10-23
ES2507579T3 (es) 2014-10-15
EE05555B1 (et) 2012-08-15
RU2001111025A (ru) 2004-02-20
AU764346B2 (en) 2003-08-14
SE9803240D0 (sv) 1998-09-24
PL347126A1 (en) 2002-03-25
CY1115688T1 (el) 2017-01-25
CY1115685T1 (el) 2017-01-25
EE05023B1 (et) 2008-06-16
CN1173694C (zh) 2004-11-03
CA2345121C (fr) 2008-06-10
BRPI9913945B8 (pt) 2022-01-25
BG65502B1 (bg) 2008-10-31
HU230342B1 (hu) 2016-02-29
DE69936393D1 (de) 2007-08-09
EP2236133B1 (fr) 2014-07-02
HU0800435D0 (en) 2008-09-29
HK1148458A1 (en) 2011-09-09
DE69936393T2 (de) 2008-03-13
MXPA01003068A (es) 2004-09-13
US8512747B2 (en) 2013-08-20
BR9913945B1 (pt) 2017-10-24
EP2236132A1 (fr) 2010-10-06
PL204264B1 (pl) 2009-12-31
BR9913945A (pt) 2001-06-12
DK2236133T3 (da) 2014-07-14
RU2193879C1 (ru) 2002-12-10
US20040213855A1 (en) 2004-10-28
ES2433930T3 (es) 2013-12-13
SK283302B6 (sk) 2003-05-02
EE200100182A (et) 2002-08-15
IL142135A0 (en) 2002-03-10
EP1652518B1 (fr) 2013-08-07
CN1326340A (zh) 2001-12-12
TR200100855T2 (tr) 2001-10-22
JP2002526439A (ja) 2002-08-20
PL201644B1 (pl) 2009-04-30
CY1119644T1 (el) 2018-04-04
PT1652518E (pt) 2013-10-01
CA2629988A1 (fr) 2000-03-30
WO2000016750A1 (fr) 2000-03-30
CA2345121A1 (fr) 2000-03-30
EP2236132B1 (fr) 2014-07-23
EP1652518A1 (fr) 2006-05-03
DK2805716T3 (en) 2017-10-16
US20120315331A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
CY1107711T1 (el) Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων
CY1106154T1 (el) Ταχεως-δρωσα φαρμακευτικη συνθεση
GR1003711B (el) Μεθοδος δια την παρασκευη φαρμακευτικων συνθεσεων δια συστηματικην διαδερμικην χορηγησιν.
DE69910803D1 (de) Fentanylzusammensetzung zur behandlung von akutem schmerz
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
DE69528057D1 (de) Tocopherolzusammensetzungen zur Abgabe von biologisch aktiven Substanzen
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
DK0822847T3 (da) Sammensætning der fremmer indgivelse af et middel ved elektrontransport
ATE288743T1 (de) Pharmazeutische trägervorrichtung welche zur verabreichung von wirkstoffen an schleimhautoberflächen geeignet ist
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
AR032293A1 (es) Estuche farmaceutico
BR9901782A (pt) Forma para dosagem de nefazodona.
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
CY1108004T1 (el) Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων για την αντιμετωπιση παθησεων σε ανθρωπους και ζωα, οι οποιες μπορουν να επηρεαστουν θepαπευτικα μεσω της αναστολης της ενepγοποιησης του nf-kb
BR9913135A (pt) Formulação oral
BR9801150A (pt) Derivados de propanolamina, processos para a preparação deles, produtos farmacêuticos compreendendo esses compostos e uso dos mesmos.
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
ES2188513T3 (es) Utilizacion de desoxipeganina para el tratamiento de la drogodependencia.
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
BR0317292A (pt) Derivados de amida de ácido antranìlico e seu uso farmacêutico